Q4 2024 Earnings Call Transcript February 4, 2025 Amgen Inc. beats earnings expectations. Reported EPS is $5.31, expectations ...

Erste Group upgraded shares of biotechnology firm Amgen (NASDAQ:AMGN) from Hold to Buy. The upgrade was primarily attributed to Amgen's financial performance, which includes a higher operating margin ...

Sales of the firm's bispecific T-cell engager Blincyto increased more than 50 percent from the fourth quarter of 2023 to 2024.

AMGN beats fourth-quarter estimates for earnings and sales. FDA places clinical hold on a phase I study on its obesity ...

Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks ...

Biosimilars have been on the market in Europe since 2007 but have had a larger impact on Amgen since 2019 as US exposure intensifies. Pressure on Prolia/Xgeva is coming in 2025. Amgen's pipeline had ...

Every year, a health care think tank called the Lown Institute ranks the 10 worst examples of "profiteering and dysfunction" ...

Driven by rapid innovations and the integration of modern technologies, the biotech sector is experiencing robust growth.

Today, Benzinga 's options scanner spotted 28 uncommon options trades for Amgen. This isn't normal. The overall sentiment of ...

Amgen has inaugurated its new drug substance facility in the US after announcing a $1bn further expansion at the North ...

The Sackler family, owners of Purdue Pharma, reached a $7.4 billion settlement to resolve mass opioid litigation. The Department of Justice filed a civil lawsuit against Walgreens over allegations it ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced its 2025 priorities and upcoming ...